Home › Compare › FRDZF vs ABBV
FRDZF yields 2222.22% · ABBV yields 3.06%● Live data
📍 FRDZF pulled ahead of the other in Year 1
Combined, FRDZF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FRDZF + ABBV for your $10,000?
noumi Limited engages in sourcing, manufacture, selling, marketing, and distribution of plant-based beverages, and dairy and nutritional ingredient products to wholesale and consumer markets. It operates in Dairy and Nutritional, and Plant Based Beverages segments. The company offers a range of ultra-heat treatment technology (UHT) shelf stable dairy milk beverage, nutritional products, and performance and adult nutritional powders. It also provides various UHT shelf stable food and beverage products, including almond, oat, soy, rice, coconut, hazelnut, and other nut-based beverages and liquid stocks. The company provides its products under the Milklab, Australia's Own, Crankt, Vital Strength, Noumi Nutritionals, Uproteinn, So Natural, and Vitalife brands. It operates in Australia, New Zealand, South Africa, China, South East Asia, and the Middle East. noumi Limited was formerly known as Freedom Foods Group Limited. The company was incorporated in 1984 and is headquartered in Ingleburn, Australia. noumi Limited is a subsidiary of Arrovest Pty Limited.
Full FRDZF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.